PHIO PHARMACEUTICALS CORP. Proceeds from Issuance of Convertible Preferred Stock
PHIO PHARMACEUTICALS CORP. (PHIO) reported Proceeds from Issuance of Convertible Preferred Stock of $8.50 million for the 12-month period ending 2012-12-31, per its 10-K filed 2014-03-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2014-03-28
- PHIO PHARMACEUTICALS CORP. proceeds from issuance of convertible preferred stock for the quarter ending 2012-12-31 was $0.00.
- PHIO PHARMACEUTICALS CORP. proceeds from issuance of convertible preferred stock for the quarter ending 2012-09-30 was $0.00.
- PHIO PHARMACEUTICALS CORP. proceeds from issuance of convertible preferred stock for fiscal 2012 was $8.50M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 6 month | Proceeds from Issuance of Convertible Preferred Stock 9 month | Proceeds from Issuance of Convertible Preferred Stock 12 month | Proceeds from Issuance of Convertible Preferred Stock 114 month | Proceeds from Issuance of Convertible Preferred Stock 117 month |
|---|---|---|---|---|---|---|
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-28 | $0.00 derived: sum of 2 quarters · filed 2014-03-28 | $8.50M 10-K · filed 2014-03-28 | |||
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $8.50M 10-Q · filed 2013-11-14 | $8.50M 10-Q · filed 2012-11-13 | |||
| 2012-06-30 | $8.50M 10-Q · filed 2013-08-14 | $8.50M 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |